The first interim safety results from a multicenter, safety surveillance study of Alzheimer's disease patients treated with ...

The FDA granted Priority Review to the supplemental BLA (sBLA) for efgartigimod alfa-fcab for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia ...

New drugs to treat Alzheimer’s disease have shown so little gain, and are so expensive, that researchers say it’s time to focus on new therapies.

People with cognitive decline or early-stage dementia saw their symptoms improve when given bespoke treatment plans that ...

People with cognitive decline or early-stage dementia saw their symptoms improve when given bespoke treatment plans that ...

A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...

A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...

I have been following the story here of the newest Alzheimers drugs, the first to show that they can actually slow the ...

A class of drugs targeting amyloid beta proteins – long associated with Alzheimer’s disease – has been widely touted as a breakthrough in neurology. But a major new review c ...

Arizonan Bob Ehlers was diagnosed with Alzheimer's six years ago and works to keep it at bay. Here are some of his tips.

Alzheimer’s Society responds to Cochrane review of ‘Amyloid-beta-targeting monoclonal antibodies for people with mild ...

For many years, Alzheimer’s disease has been one of the biggest challenges in medicine. It slowly damages memory, thinking, ...